Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.49 |
| ▸ | GAA | P10253 | 9/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | GFER | P55789 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PLEC | Q15149 | 1/20 | 0.49 |
| ▸ | TPMT | P51580 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435829 | 0.83 | PARP1 (0.55) | KDM4EMAPTHSD17B10ALDH1A1L3MBTL1 | |
| SCHEMBL4801156 | 0.83 | CDC25B (0.55) | CDC25BKDM4EGAAMAPTHSD17B10 | |
| SCHEMBL7109398 | 0.81 | PRKCI (0.56) | KDM4EGAAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL6565452 | 0.80 | MAPK1 (0.57) | KDM4EGAAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL29351778 | 0.79 | CDC25B (0.61) | CDC25BKDM4EGAAMAPTHSD17B10 | |
| SCHEMBL29364242 | 0.79 | TPMT (0.58) | KDM4EGAAMAPTALDH1A1TPMT | |
| SCHEMBL2723610 | 0.79 | TPMT (0.58) | KDM4EGAAMAPTALDH1A1TPMT | |
| SCHEMBL4824967 | 0.79 | CDC25B (0.61) | CDC25BKDM4EGAAMAPTHSD17B10 | |
| SCHEMBL77186 | 0.79 | CDC25B (0.61) | CDC25BKDM4EGAAMAPTHSD17B10 | |
| SCHEMBL19996930 | 0.78 | HDAC1 (0.41) | KDM4EGAAMAPTHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111053763-B | Application of bifunctional iodine-containing aromatic acid in resisting EV71 virus | 湖北工业大学 | 2021-04-02 | — | — | CN | claimed |
| CN-111116395-A | Multi-iodo aromatic acid compound and application thereof in resisting adenovirus 7 | 湖北工业大学 | 2020-05-08 | — | — | CN | claimed |
| CN-111053763-A | Application of bifunctional iodine-containing aromatic acid in resisting EV71 virus | 湖北工业大学 | 2020-04-24 | — | — | CN | claimed |
| US-5932743-A | Methods for the solid phase synthesis of substituted indole compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-08-03 | — | — | US | claimed |
| WO-1999009007-A1 | SOLID PHASE SYNTHESIS OF 2,3-DISUBSTITUTED INDOLE COMPOUNDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-25 | — | — | WO | claimed |
| WO-2025041781-A1 | RESIST COMPOSITION, RESIST PATTERN FORMING METHOD, COMPOUND, AND POLYMER COMPOUND | 東京応化工業株式会社 | 2025-02-27 | — | — | WO | disclosed |
| WO-2024176701-A1 | RESIST COMPOSITION, RESIST PATTERN FORMATION METHOD, COMPOUND, AND POLYMER COMPOUND | 東京応化工業株式会社 | 2024-08-29 | — | — | WO | disclosed |
| CN-118139508-A | Two-dimensional three-dimensional hybrid perovskite light absorption material and preparation method thereof, and perovskite solar cell comprising same | 正泰新能科技股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11628144-B2 | Iniparib formulations and uses thereof | TRIACT THERAPEUTICS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| CN-111116395-B | Multi-iodo aromatic acid compound and application thereof in resisting adenovirus 7 | 湖北工业大学 | 2023-04-07 | — | — | CN | disclosed |
| EP-1414441-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH HETEROBICYCLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-05-06 | — | — | EP | disclosed |
| EP-1414797-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-05-06 | — | — | EP | disclosed |
| US-20040024190-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-02-05 | — | — | US | disclosed |
| US-20030176433-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-09-18 | — | — | US | disclosed |
| WO-2003010141-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH A HETEROBICYCLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003010140-A2 | HEPATITIS C VIRUS POLYMERASE INHIBITORS WITH HETEROBICYCLIC STRUCTURE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-02-06 | — | — | WO | disclosed |
| US-5932743-A | Methods for the solid phase synthesis of substituted indole compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1999009007-A1 | SOLID PHASE SYNTHESIS OF 2,3-DISUBSTITUTED INDOLE COMPOUNDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | CDC25B 255/4885KDM4E 4039/4885GAA 992/4885 |
| US-20030176433-A1 | Viral polymerase inhibitors | NR4A1, RCOR1, RER1 | CDC25B 3688/4885KDM4E 2739/4885GAA 3150/4885 |
| US-20040024190-A1 | Viral polymerase inhibitors | RCOR1, NR4A1, RER1 | CDC25B 4268/4885KDM4E 2494/4885GAA 3501/4885 |
| US-11628144-B2 | Iniparib formulations and uses thereof | INPP5B, INPPL1, PARP3 | CDC25B 561/4885KDM4E 3120/4885GAA 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.